Horizon Pharma gets additional notice of allowance with claims covering Pennsaid 2%

Horizon Pharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number entitled “Treatment of Pain with Topical Diclofenac” for a drug Pennsaid 2% w/w.

Pennsaid 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s).

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. It represents the 15th allowed U.S. patent for Pennsaid 2%

The U.S. patent scheduled to issue from this application will expire October 17, 2027.

After issuance, Horizon plans to list the U.S. patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s